Share This Article:

Development of a New Approach for the Therapy of Prostate Cancer with SPOP Mutations

Abstract Full-Text HTML XML Download Download as PDF (Size:471KB) PP. 841-848
DOI: 10.4236/jct.2015.610092    2,917 Downloads   3,562 Views   Citations

ABSTRACT

Advanced prostate cancer is treated with androgen deprivation, but most patients eventually progress and need new therapy. Recent genomic/exomic sequencing identified SPOP as the most frequently mutated gene in 6% - 15% of prostate cancer. Based on the function of SPOP as a ubiquitin ligase in protein degradation, it was hypothesized that loss-of-function mutations of SPOP led to accumulation of SPOP substrates that enhance androgen receptor activity and facilitate prostate cancer formation. SPOP substrates could thus be potential targets for treatment of androgen-sensitive prostate cancer. PubMed and BLAST search identified that Gli, SRC-3, and AWP1 are SPOP substrates, and that inhibition of PRK-1, a binding partner of AWP1, by lestaurtinib suppressed androgen receptor activity. LNCaP, PC3, DU145 and 22RV1 prostate cancer cells were used to evaluate the effect of lestaurtinib. LNCaP cells, an androgen-sensitive prostate cancer cell line, were the most sensitive. SRC-3 protein decreased when LNCaP cells were treated with lestaurtinib; whereas PRK-1 increased in nucleus after lestaurtinib treatment. These data suggest that lestaurtinib modulates SRC-3 and PRK-1 to induced cell death in androgen-sensitive prostate cancer, and could be a useful agent for future development for prostate cancer with SPOP mutations.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Lu, D. , Lee, J. , Lee, A. and Lee, R. (2015) Development of a New Approach for the Therapy of Prostate Cancer with SPOP Mutations. Journal of Cancer Therapy, 6, 841-848. doi: 10.4236/jct.2015.610092.

References

[1] Barbieri, C.E., Baca, S.C., Lawrence, M.L., et al. (2012) Exome Sequencing Identifies Recurrent SPOP, FOXA1 and MED12 Mutations in Prostate Cancer. Nature Genetics, 44, 685-689.
http://dx.doi.org/10.1038/ng.2279
[2] Kwon, J.E., La, M., Oh, K.H., et al. (2006) BTB Domain-Containing Speckle-Type POZ Protein (SPOP) Serves as an Adaptor of Daxx for Ubiquitination by Cul3-Based Ubiquitin Ligase. The Journal of Biological Chemistry, 281, 12664-12672.
http://dx.doi.org/10.1074/jbc.M600204200
[3] Geng, C., He, B., Xu, L., Barbieri, C.E., Eedunuri, V.K., et al. (2013) Prostate Cancer-Associated Mutations in Speckle-Type POZ Protein (SPOP) Regulate Steroid Receptor Coactivator 3 Protein Turnover. Proceedings of the National Academy of Sciences of the USA, 110, 6997-7002.
http://dx.doi.org/10.1073/pnas.1304502110
[4] Li, C., Ao, J., Fu, J., et al. (2011) Tumor-Suppressor Role for the SPOP Ubiquitin Ligase in Signal-Dependent Proteolysis of the Oncogenic Co-Activator SRC-3/AIB1. Oncogene, 30, 4350-4364.
http://dx.doi.org/10.1038/onc.2011.151
[5] Zhang, Q., Zhang, L., Wang, B., et al. (2006) A Hedgehog-Induced BTB Protein Modulates Hedgehog Signaling by Degrading Ci/Gli Transcription Factor. Developmental Cell, 10, 719-729.
http://dx.doi.org/10.1016/j.devcel.2006.05.004
[6] Theurillat, J.P., Udeshi, N.D., Errington, W.J., Svinkina, T., Baca, S.C., et al. (2014) Prostate Cancer. Ubiquitylome Analysis Identifies Dysregulation of Effector Substrates in SPOP-Mutant Prostate Cancer. Science, 346, 85-89.
http://dx.doi.org/10.1126/science.1250255
[7] Xu, J., Wu, R.C. and O’Malley, B.W. (2009) Normal and Cancer-Related Functions of the p160 Steroid Receptor Co-Activator (SRC) Family. Nature Reviews Cancer, 9, 615-630.
http://dx.doi.org/10.1038/nrc2695
[8] Gnanapragasam, V.J., Leung, H.Y., Pulimood, A.S., Neal, D.E. and Robson, C.N. (2001) Expression of RAC 3, a Steroid Hormone Receptor Co-Activator in Prostate Cancer. British Journal of Cancer, 85, 1928-1936.
http://dx.doi.org/10.1054/bjoc.2001.2179
[9] Zhou, H.J., Yan, J., Luo, W., Ayala, G., Lin, S.H., Erdem, H., Ittmann, M., Tsai, S.Y. and Tsai, M.J. (2005) SRC-3 Is Required for Prostate Cancer Cell Proliferation and Survival. Cancer Research, 65, 7976-7983.
[10] Kohler, J., Erlenkamp, G., Eberlin, A., Rumpf, T., Slynko, I., Metzger, E., Schüle, R., Sippl, W. and Jung, M. (2012) Lestaurtinib Inhibits Histone Phosphorylation and Androgen-Dependent Gene Expression in Prostate Cancer Cells. PLoS One, 7, e34973.
http://dx.doi.org/10.1371/journal.pone.0034973
[11] Metzger, E., Müller, J.M., Ferrari, S., Buettner, R. and Schüle, R. (2003) A Novel Inducible Transactivation Domain in the Androgen Receptor: Implications for PRK in Prostate Cancer. The EMBO Journal, 22, 270-280.
http://dx.doi.org/10.1093/emboj/cdg023
[12] Weeraratna, A.T., Dalrymple, S.L., Lamb, J.C., Denmeade, S.R., Miknyoczki, S., Dionne, C.A. and Isaacs, J.T. (2001) Pan-Trk Inhibition Decreases Metastasis and Enhances Host Survival in Experimental Models as a Result of Its Selective Induction of Apoptosis of Prostate Cancer Cells. Clinical Cancer Research, 7, 2237-2245.
[13] Levis, M., Ravandi, F., Wang, E.S., Baer, M.R., Perl, A., Coutre, S., Erba, H., Stuart, R.K., et al. (2011) Results from a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for Patients with FLT3 Mutant AML in First Relapse. Blood, 117, 3294-3301.
http://dx.doi.org/10.1182/blood-2010-08-301796
[14] Zhang, Q., Shi, Q., Chen, Y., Yue, T., Li, S., Wang, B. and Jiang, J. (2009) Multiple Ser/Thr-Rich Degrons Mediate the Degradation of Ci/Gli by the Cul3-HIB/SPOP E3 Ubiquitin Ligase. Proceedings of the National Academy of Sciences of the United States of America, 106, 21191-21196.
http://dx.doi.org/10.1073/pnas.0912008106
[15] Chang, E.J., Ha, J., Kang, S.S., Lee, Z.H. and Kim, H.-H. (2011) AWP1 Binds to Tumor Necrosis Factor Receptor-Associated Factor 2 (TRAF2) and Is Involved in TRAF2-Mediated Nuclear Factor-κB Signaling. The International Journal of Biochemistry & Cell Biology, 43, 1612-1620.
http://dx.doi.org/10.1016/j.biocel.2011.07.010
[16] Duan, W., Sun, B., Li, T.W., Tan, B.J., Lee, M.K. and Teo, T.S. (2000) Cloning and Characterization of AWP1, a Novel Protein That Associates with Serine/Threonine Kinase PRK-1 in Vivo. Gene, 256, 113-121.
http://dx.doi.org/10.1016/S0378-1119(00)00365-6
[17] Collins, C., Carducci, M.A., Eisenberger, M.A., Isaacs, J.T., Partin, A.W., Pili, R., Sinibaldi, V.J., Walczak, J.S. and Denmeade, S.R. (2007) Preclinical and Clinical Studies with the Multi-Kinase Inhibitor CEP-701 as Treatment for Prostate Cancer Demonstrate the Inadequacy of PSA Response as a Primary Endpoint. Cancer Biology & Therapy, 6, 1360-1367.
http://dx.doi.org/10.4161/cbt.6.9.4541
[18] Yi, P., Feng, Q., Amazit, L., Lonard, D.M., Tsai, S.Y., Tsai, M.J. and O’Malley, B.W. (2008) Atypical Protein Kinase C Regulates Dual Pathways for Degradation of the Oncogenic Coactivator SRC-3/AIB1. Molecular Cell, 29, 465-476.
http://dx.doi.org/10.1016/j.molcel.2007.12.030
[19] Festuccia, C., Muzi, P., Gravina, G.L., Millimaggi, D., Speca, S., Dolo, V., Ricevuto, E., Vicentini, C. and Bologna, M. (2007) Tyrosine Kinase Inhibitor CEP-701 Blocks the NTRK1/NGF Receptor and Limits the Invasive Capability of Prostate Cancer Cells in Vitro. International Journal of Oncology, 30, 193-200.
http://dx.doi.org/10.3892/ijo.30.1.193
[20] George, D.J., Dionne, C.A., Jani, J., Angeles, T., Murakata, C., Lamb, J. and Isaacs, J.T. (1999) Sustained in Vivo Regression of Dunning H Rat Prostate Cancers Treated with Combinations of Androgen Ablation and Trk Tyrosine Kinase Inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Research, 59, 2395-2401.

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.